Ivis Chaple, PhD
Ivis Chaple, PhD
Program: BioEngineering
-
Overview
Our research theme is centered around nuclear medicine and molecular imaging towards oncology. My group focus on the development of radiopharmaceuticals for diagnostic imaging and targeted therapy of various types of cancer.
Associations
- BioEngineering
-
Research Interest
More specifically, I am interested in radioisotope production of exotic radionuclides, their chemistry in biological environments and clinical translation. I am also interested in studying how ionizing radiation might modulate the tumor microenvironment, and how we can leverage that to enhance treatment outcomes.
-
Publications
- Osborne D, Cutler CS, Chaple IF, Ribeiro Pereira PM, Peterson TE, Solingapuram Sai KK, Wang J, Scott PJH, Chen DL. Industry-Academic Collaboration in Nuclear Medicine: Proceedings from the 2024 CMIIT Industry Partners Circle. J Nucl Med. 2026 Sep.67(9):1365-1368. Pubmedid: 42209122.
- Sanwick AM, Alves DS, Haugh KN, Barrera FN, Chaple IF. [64Cu]Cu-DOTA-TYPE7: a targeted PET radiotracer for imaging EphA2+ tumors. Npj Imaging. 2026 May.4(1). Pubmedid: 42082632. Pmcid: PMC13139581.
- Sanwick AM, Haugh KN, Osborne DR, Dawson JW, Chaple IF. Enhanced pre-therapy dosimetry for SSTR PET: A head-to-head preclinical assessment of [89Zr]Zr-DFO-TOC and [89Zr]Zr-DFO-TATE. Nucl Med Biol. 2026 Aug.158-159:109655. Pubmedid: 42378940.
- Williams EJ, Racz DG, Perry KA, Fassbender ME, Chaple IF. Processing iridium foil targets for the production of radioplatinum isotopes. Appl Radiat Isot. 2026 Apr.230:112441. Pubmedid: 41616710.
- Racz DG, Chaple IF. Platinum group metals for nuclear medicine, a luxurious dream or the future of imaging and therapy: a review. Front Nucl Med. 2025 Sep.5:1656374. Pubmedid: 41018941. Pmcid: PMC12460398.
- Sanwick AM, Chaple IF. Radiocobalt theranostic applications: current landscape, challenges, and future directions. Front Nucl Med. 2025 Aug.5:1663748. Pubmedid: 40842662. Pmcid: PMC12364805.
- Haugh KN, Sanwick AM, Chaple IF. Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade. Front Nucl Med. 2025 Aug.5:1655419. Pubmedid: 40851810. Pmcid: PMC12367690.
- Scott PJ, Penuelas I, Rey A, Aime S, Ambikalmajan PMR, Antunes IF, Cleeren F, Liu Z, Ellis B, Kahts M, Ekoume FP, Chaple IF, Bernardes E, Behe M, Huang YY, Mikolajczak R, Furumoto S, Elrefaei A, Kopka K. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem. 2024 Sep.9(1):67. Pubmedid: 39283414. Pmcid: PMC11405612.
- Sanwick AM, Haugh KN, Williams EJ, Perry KA, Thiele NA, Chaple IF. [89Zr]Zr-DFO-TOC: a novel radiopharmaceutical for PET imaging of somatostatin receptor positive neuroendocrine tumors. EJNMMI Radiopharm Chem. 2024 Dec.9(1):88. Pubmedid: 39693037. Pmcid: PMC11655904.
- Sanwick AM, Chaple IF. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review. Front Oncol. 2024.14:1445191. Pubmedid: 39239273. Pmcid: PMC11374632.
- Koller AJ, Saini S, Chaple IF, Joaqui-Joaqui MA, Paterson BM, Ma MT, Blower PJ, Pierre VC, Robinson JR, Lapi SE, Boros E. A General Design Strategy Enabling the Synthesis of Hydrolysis-Resistant, Water-Stable Titanium(IV) Complexes. Angew Chem Int Ed Engl. 2022 May.61(22):e202201211. Pubmedid: 35263017.
- Chaple IF, Houson HA, Koller A, Pandey A, Boros E, Lapi SE. 45Ti targeted tracers for PET imaging of PSMA. Nucl Med Biol. 2022 Jun.108-109:16-23. Pubmedid: 35189565.
- Adams MK, Belyaeva OV, Wu L, Chaple IF, Dunigan-Russell K, Popov KM, Kedishvili NY. Characterization of subunit interactions in the hetero-oligomeric retinoid oxidoreductase complex. Biochem J. 2021 Oct.478(19):3597-3611. Pubmedid: 34542554. Pmcid: PMC8740524.
- Derke RM, Barron AJ, Billiot CE, Chaple IF, Lapi SE, Broderick NA, Gray MJ. The Cu(II) Reductase RclA Protects Escherichia coli against the Combination of Hypochlorous Acid and Intracellular Copper. MBio. 2020 Sep.11(5). Pubmedid: 32994322. Pmcid: PMC7527725.
- Chaple IF, Thiele K, Thaggard G, Fernandez S, Boros E, Lapi SE. Optimized methods for production and purification of Titanium-45. Appl Radiat Isot. 2020 Dec.166:109398. Pubmedid: 32911440.
- Chaple IF, Lapi SE. Production and Use of the First-Row Transition Metal PET Radionuclides 43,44Sc, 52Mn, and 45Ti. J Nucl Med. 2018 Nov.59(11):1655-1659. Pubmedid: 30262514.